- 'Yes' vote prevails in Kazakhstan nuclear plant vote: TV
- 'Difficult day': Oct 7 commemorations begin with festival memorial
- Commemorations begin for anniversary of attack on Israel
- Lewandowski hat-trick powers Liga leaders Barca to Alaves victory
- 'Nothing gets in way of team,' says Celtics' MVP hopeful Tatum
- India maintain Pakistan stranglehold as Windies cruise at Women's T20 World Cup
- 'We will win!': Mozambique's ruling party confident at final vote rally
- Tunisia voting ends as Saied eyes re-election with critics behind bars
- Florida braces for Milton, FEMA head slams 'dangerous' Helene misinformation
- Postecoglou slams 'unacceptable' Spurs after 'terrible' loss at Brighton
- Marmoush double denies Bayern outright Bundesliga top spot
- Rallies worldwide call for Gaza, Lebanon ceasefire
- Maresca hails Chelsea's 'fighting' spirit after draw with 10-man Forest
- New 'Joker' film, a dark musical, tops N.America box office
- Man Utd stalemate keeps Ten Hag in danger, Spurs rocked by Brighton
- Drowned by hurricane, remote N.Carolina towns now struggle for water
- Vikings hold off Jets in London to stay unbeaten
- Ahead of attack anniversary, Netanyahu says: 'We will win'
- West Indies cruise to T20 World Cup win over Scotland
- Arshdeep, Chakravarthy help India hammer Bangladesh in T20 opener
- Lewandowski's quickfire hat-trick powers Liga leaders Barca to Alaves victory
- Man Utd fire another blank in Aston Villa stalemate
- Lewandowski treble powers Liga leaders Barca to Alaves victory
- Russian activist killed on front line in Ukraine
- Openda strike briefly sends Leipzig top of Bundesliga
- Goal-shy Man Utd have to 'step up', says Ten Hag
- India bowl out Bangladesh for 127 in T20 opener
- Madueke rescues Chelsea in draw with 10-man Forest
- Beckett's belief rewarded as Bluestocking storms to Arc glory
- Trump on the stump, Harris hits airwaves in razor-edge US election
- Flash flooding kills three in northern Thailand
- Kaur leads India to victory over Pakistan in Women's T20 World Cup
- Juventus held by Cagliari after late penalty drama
- In France's Marseille, teen 'stabbed 50 times' then burned alive
- Ruthless Gauff beats Muchova in straight sets to win China Open
- India restrict Pakistan to 105-8 in Women's T20 World Cup
- England target repeat of Pakistan Test whitewash
- Penrith Panthers win fourth straight NRL title after downing Storm
- Weary Sinner happy for day off after battling into Shanghai last 16
- Pakistan's Masood warns England still a force without Stokes
- Madrid's Carvajal to miss several months after serious knee injury
- Israel pounds Lebanon ahead of Hamas attack anniversary
- Two elephants die in flash flooding in northern Thailand
- Sabalenka targets world number one and Wuhan hat-trick
- Toddler among 4 dead in migrant Channel crossings
- Tunisia votes with Saied set for re-election
- Bagnaia sets 'example' with Japan MotoGP win to cut gap on Martin
- Intense Israeli bombing rocks Beirut ahead of war anniversary
- Mozambique vote: no suspense but some disillusion
- Austrian rapper channels anti-racist rage in Romani hip-hop songs
France's Sanofi to seek Covid vaccine approval after delays
French pharmaceuticals giant Sanofi said Wednesday that its Covid-19 vaccine, developed with Britain's GSK, had delivered positive results after nearly a year of delays left it lagging far behind its rivals.
The two drugmakers said they will "seek regulatory authorisation" for their vaccine in the United States and the European Union following phase 3 trials involving thousands of people.
The trials indicated that the vaccine was 100 percent effective against severe Covid disease and hospitalisation, Sanofi said in a statement.
It was also more than 50 percent effective against all symptomatic Covid, the statement added.
Sanofi's vice-president for vaccines Thomas Triomphe said the data was "similar to the recent clinical data from authorised vaccines".
He also emphasised that no other phase 3 study "has been undertaken during this period with so many variants of concern, including Omicron."
The announcement of the positive trials -- which have not yet been released as is normal practice -- puts the vaccine on the last hurdle before a possible market launch.
Sanofi's share price rose nearly 1.5 percent on the Paris stock exchange at midday.
- Wounded French pride -
If the vaccine receives authorisation, it will mark the end of Sanofi's long struggle to develop a Covid vaccine following numerous setbacks.
The French firm originally hoped to announce such results by mid-2021.
But the date was pushed back by six months due to a dosing error, then late last year was delayed again after difficulties finding people who had never been infected with Covid to take part in the trials.
The delays -- and the renowned Pasteur Institute abandoning plans to develop its own vaccine in early 2021 -- dented the pride of a country that considers itself a leader on pharmaceutical technology.
Sanofi also abandoned a previous vaccine project based on the mRNA technology used by its quicker rivals Pfizer/BioNTech and Moderna, whose jabs have formed the backbone of vaccination efforts in many countries.
Sanofi is now focused on a vaccine using a slightly less innovative technique based on recombinant protein technology, also seen in the Novavax jab which is about to be introduced in France.
There are hopes that Sanofi's jab could appeal more to unvaccinated people who remain sceptical of mRNA technology, despite the reams of evidence on its effectiveness.
GlaxoSmithKline's vaccines head Roger Connor said in the statement that the jab "uses a well-established approach that has been applied widely to prevent infection with other viruses including pandemic flu".
The EU has already pre-ordered millions of doses of the vaccine, and Sanofi is likely to play a role in booster campaigns around the world.
And with many countries -- particularly in the developing world -- struggling to inoculate their population, there is likely still a market for newer vaccines.
L.Harper--AMWN